Neoadjuvant chemotherapy (NAC) is the standard treatment for muscle-invasive bladder cancer (MIBC), yet 40% of patients progress, emphasizing the need for biomarkers predictive for response or chemoresistance. Gene expression-based subtypes may serve as biomarkers, though which subtypes will respond, notably when it comes to the basal subtype, remains contentious.
This post-hoc study analyzed 300 NAC-treated patients enrolled in the GETUG/AFU VESPER trial, with transurethral diagnostic FFPE which underwent pathological review prior to being sequenced. "Mixed" subtype was defined for tumors displaying at least two different Consensus molecular subtypes in separate regions. We evaluated the association between molecular subtypes and outcome after NAC. Tumours with remaining tissue at cystectomy (n=83) were compared with pre-treatment tumours.
Cases were classified Basal/squamous (Ba/Sq) (n=84), Luminal Unstable (n=57), Stroma-rich (n=53), Mixed (n=48), Luminal Papillary (n=39), Luminal Non-Specific (n=18) and Neuroendocrine-like (n=1), with 30/48 Mixed cases including a Ba/Sq component. Compared with other molecular subtypes in a multivariate Cox model, Ba/Sq (Pure or Mixed) patients had an increased hazard ratio of progression free survival (HR:2.0, 95% CI 1.36-3.0). Mixed tumors were associated with decreased metabolic activity that could account for chemoresistance. Ba/Sq and Mixed non-responders mostly maintained their subtype at cystectomy and have fewer myeloid dendritic cells after NAC. Tumors classified luminal papillary at TURBT exhibited an increase of T CD4+ and macrophage signatures after NAC. Other subtypes did not show significant immune changes after NAC. Our study design relied on detailed pathological review, which precluded evaluating the Mixed subtype in published datasets. Furthermore, the sample size for post-NAC analyses constrained the statistical power of these findings.
Our findings underscore the importance of recognizing intra-tumor heterogeneity in MIBC, its role in chemoresistance associated with Ba/Sq subtype and provide valuable insights that could help future treatment development and improve patient outcomes.
Annals of oncology : official journal of the European Society for Medical Oncology. 2024 Sep 17 [Epub ahead of print]
C S Groeneveld, C Pfister, S Culine, V Harter, C Krucker, J Fontugne, V Dixon, N Sirab, I Bernard-Pierrot, A de Reyniès, F Radvanyi, Y Allory, VESPER trial investigators
Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France; Centre de Recherche des Cordeliers, Université Paris-Cité, UMRS1138, Paris, France., Université de Rouen Normandie, Inserm, CIC Inserm 1404, Onco-Urology, Hôpital; Universitaire Charles Nicolle, Department of Urology, Rouen, France., Université de Paris Cité, AP-HP, Hôpital Saint-Louis, Department of Medical Oncology, Paris, France., Centre François Baclesse, North-West Canceropole Data Center, Caen, France., Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France., Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France; Université Paris-Saclay, UVSQ, Institut Curie, Department of Pathology, Saint-Cloud, France., Centre de Recherche des Cordeliers, Université Paris-Cité, UMRS1138, Paris, France., Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France; Université Paris-Saclay, UVSQ, Institut Curie, Department of Pathology, Saint-Cloud, France. Electronic address: .